Achievement of Goals in U.S. Diabetes Care, 1999–2010
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tracking national progress in diabetes care may aid in the evaluation of past efforts and identify residual gaps in care. METHODS: We analyzed data for adults with self-reported diabetes from the National Health and Nutrition Examination Survey and the Behavioral Risk Factor Surveillance System to examine risk-factor control, preventive practices, and risk scores for coronary heart disease over the 1999-2010 period. RESULTS: From 1999 through 2010, the weighted proportion of survey participants who met recommended goals for diabetes care increased, by 7.9 percentage points (95% confidence interval [CI], 0.8 to 15.0) for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points (95% CI, 3.0 to 15.8) for individualized glycemic targets, 11.7 percentage points (95% CI, 5.7 to 17.7) for blood pressure (target, <130/80 mm Hg), and 20.8 percentage points (95% CI, 11.6 to 30.0) for lipid levels (target level of low-density lipoprotein [LDL] cholesterol, <100 mg per deciliter [2.6 mmol per liter]). Tobacco use did not change significantly, but the 10-year probability of coronary heart disease decreased by 2.8 to 3.7 percentage points. However, 33.4 to 48.7% of persons with diabetes still did not meet the targets for glycemic control, blood pressure, or LDL cholesterol level. Only 14.3% met the targets for all three of these measures and for tobacco use. Adherence to the recommendations for annual eye and dental examinations was unchanged, but annual lipid-level measurement and foot examination increased by 5.5 percentage points (95% CI, 1.6 to 9.4) and 6.8 percentage points (95% CI, 4.8 to 8.8), respectively. Annual vaccination for influenza and receipt of pneumococcal vaccination for participants 65 years of age or older rose by 4.5 percentage points (95% CI, 0.8 to 8.2) and 6.9 percentage points (95% CI, 3.4 to 10.4), respectively, and daily glucose monitoring increased by 12.7 percentage points (95% CI, 10.3 to 15.1). CONCLUSIONS: Although there were improvements in risk-factor control and adherence to preventive practices from 1999 to 2010, tobacco use remained high, and almost half of U.S. adults with diabetes did not meet the recommended goals for diabetes care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Still, many do not meet the recommended goals for diabetes care [7-9]; in Norway, research has shown that only 20% attain the target for metabolic control for glycated hemoglobin A1c (HbA1c), blood pressure, and lipid level, although the quality of care has improved [8].”
In the citing paper
“there is evidence that measures of 10-year CHD risk among U.S. adults with diabetes have improved signi fi cantly over the past decade (2)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 2
- Ahmann AJ, 2007, Am J Manag Care, 13, S41
- Gary TL, 2003, Ethn Dis, 13, 47
Cited by
Items 201–300 of 978
Sakboonyarat, B., Pima, W., Chokbumrungsuk, C., Pimpak, T., Khunsri, S., Ukritchon, S., Imjaijitt, W., Mungthin, M., Kaewput, W., Bhopdhornangkul, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93733-4 · Cited by 70
Venkatraman, S., Echouffo-Tcheugui, J. B., Selvin, E., & Fang, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47656 · Cited by 60
Community health workers in diabetes care: A systematic review of randomized controlled trials.
Trump, L. J., & Mendenhall, T. J. (2017) · Families, Systems, & Health · doi:10.1037/fsh0000283 · Cited by 53
Treating complexity: Collaborative care for multiple chronic conditions
Chwastiak, L., Vanderlip, E., & Katon, W. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2014.969689 · Cited by 53
Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review
Rodriguez, P., Martin, V. T. S., & Pantalone, K. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01530-9 · Cited by 67
“Despite the overwhelming evidence that early glycemic control offers significant long-term benefits, the reality is that a substantial number of patients still struggle to meet glycemic targets [8, 9].”
BackgroundMethodDiabetes management in the real world and the impact of adherence to guideline recommendations
Lian, J., & Liang, Y. M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.952716 · Cited by 66
Pantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Kong, S. X., Ji, X., Ganguly, R., Milinovich, A., Weng, W., Bauman, J. M., Petraro, P., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0968 · Cited by 60
Flores‐Hernández, S., Saturno-Hernández, P. J., Reyes‐Morales, H., Barrientos‐Gutiérrez, T., Villalpando, S., & Hernández‐Ávila, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133958 · Cited by 55
“With regard to Mexico, compliance with quality of care indicators in our study is similar to the findings of another study that involved reviewing records [11].”
ResultBenefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 60
Rossi, M. C., Candido, R., Ceriello, A., Cimino, A., Bartolo, P. D., Giorda, C. B., Esposito, K., Lucisano, G., Maggini, M., Mannucci, E., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0688-6 · Cited by 53
“Less frequently, quality of care indicators was used to assess trends over time [23] or to evaluate the results of benchmarking activities [24].”
Makam, A. N., & Nguyen, O. K. (2017) · Circulation · doi:10.1161/circulationaha.116.022622 · Cited by 52
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
“developing long-term micro- and macrovascular complications of T2D [10, 11].”
BackgroundOwens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 57
“Indeed, only 14% of individuals achieve recognized targets for glucose, blood pressure and lipids (alongside non-smoking status).(8) Of considerable concern, in Eastern Europe, Latin America and Asia, 36% of patients with T2DM have never had”
BackgroundHeart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
“Moreover, only 14% of patients meet targets for glycaemic control, blood pressure, cholesterol levels or abstinence from smoking.(3) In addition to these frustrating results, there seems to”
BackgroundZhong, V. W., Yu, D., Zhao, L., Yang, Y., Li, X., Li, Y., Huang, Y., Ding, G., & Wang, H. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0442 · Cited by 54
“In accordance with the Chinese diabetes guidelines and evidence from the literature (8, 10, 11), the individualized HbA1c target was specified as less than 6.”
MethodMor, A., Berencsi, K., Nielsen, J. S., Rungby, J., Friborg, S. G., Brandslund, I., Christiansen, J. S., Vaag, A. A., Beck‐Nielsen, H., Sørensen, H. T., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw345 · Cited by 61
Understanding diabetes and the role of psychology in its prevention and treatment.
Hunter, C. M. (2016) · American Psychologist · doi:10.1037/a0040344 · Cited by 51
Nelson, A. J., Peterson, E. D., & Pagidipati, N. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.001 · Cited by 52
Hayashino, Y., Suzuki, H., Yamazaki, K., Goto, A., Izumi, K., & Noda, M. (2015) · Diabetic Medicine · doi:10.1111/dme.12949 · Cited by 56
Cosmo, S. D., Viazzi, F. C., Pacilli, A., Giorda, C. B., Ceriello, A., Gentile, S., Russo, G. T., Rossi, M. C., Nicolucci, A., Guida, P., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv101 · Cited by 57
“that although there have been improvements over the last decade, almost half of American adults with diabetes do not meet the recommended goals for diabetes care [28].”
BackgroundMirabelli, M., CHIEFARI, E. D., Caroleo, P., Vero, R., Brunetti, F. S., Corigliano, D. M., Arcidiacono, B., FOTI, D. P., Puccio, L., & Brunetti, A. (2019) · Journal of Diabetes Research · doi:10.1155/2019/3971060 · Cited by 55
“%) recommended by the American Diabetes Association [4], which would significantly reduce the incidence and progression of microvascular complications [5–8].”
BackgroundPan, S., Liu, Z., Shi, S., Ma, X., Song, W., Guan, G., Zhang, Y., Zhu, S., Liu, F., Liu, B., et al. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.050 · Cited by 52
Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007–2012
Bullard, K. M., Ali, M. K., Imperatore, G., Geiss, L. S., Saydah, S., Albu, J., Cowie, C. C., Sohler, N., Albright, A. L., & Gregg, E. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125249 · Cited by 51
“Health reforms are underway which may improve access and transform healthcare from a fee-for-service to fee-for-quality paradigm, which, in turn, may impact current gaps in diabetes care [36].”
BackgroundSelf-citationDiabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
Norhammar, A., Mellbin, L., & Cosentino, F. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317709554 · Cited by 49
Declines in the Incidence of Diabetes in the U.S.—Real Progress or Artifact?
Selvin, E., & Ali, M. K. (2017) · Diabetes Care · doi:10.2337/dc16-2442 · Cited by 50
“priate care, and possibly health outcomes (12,27).”
Self-citationBakke, Å., Cooper, J. G., Thue, G., Skeie, S., Carlsen, S., Dalen, I., Løvaas, K. F., Madsen, T. V., Oord, E. R., Berg, T. J., et al. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000459 · Cited by 54
“5%).(16) This indicates that more patients with diabetes should start lipid-lowering therapy in Norway and that GPs should maintain efforts to achieve the strict LDL target in high-risk persons with CVD.”
BackgroundResultInfluentialLower extremity artery disease in patients with type 2 diabetes
Buso, G., Aboyans, V., & Mazzolai, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880044 · Cited by 48
“Of note, although percentages of diabetic patients with CV disease reaching LDL targets increased over time, this goal was not achieved in several cases.(47) In general, the safety profile of statins is acceptable and their administration is advised in all patients with symptomatic LEAD, including those with T2DM.”
BackgroundRethinking the Viability and Utility of Inhaled Insulin in Clinical Practice
Heinemann, L., & Parkin, C. G. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4568903 · Cited by 48
“Despite considerable advances in pharmacotherapy, insulin delivery systems, and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose control, reflected by not reaching their HbA1c goals [15, 16].”
BackgroundDevineni, D., Vaccaro, N., Polidori, D., Rusch, S., & Wajs, E. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.02.022 · Cited by 49
“Plasma canagliflozin concentrations achieved with 300 mg/d were sufficient to provide near-maximal lowering of RTG throughout the full 24-hour period in patients with T2DM.28 Furthermore, in other studies, twice-daily doses of canagliflozin 300 mg achieved mean plasma AUCτ,ss 10 that was 68% higher than that with the…”
BackgroundCha, S., Park, Y., Yun, J., Lee, S., Ahn, Y., Kim, S., & Ko, S. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.001 · Cited by 54
“Although there has been a significant improvement on risk management of coronary heart disease (CHD) over the past decade, many patients with T2DM have not achieved overall target of multifactorial risk factor for preventing CVD [5].”
BackgroundAfkarian, M., Polsky, S., Parsa, A., Aronson, R., Caramori, M. L., Cherney, D. Z. I., Crandall, J. P., de Boer, I. H., Elliott, T. G., Galecki, A. T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0342 · Cited by 50
“, blood pressure, HbA1c, and RASI use) than has been reported for the general population with diabetes and DKD (36,37), likely because of the substantial recruitment from specialist diabetes centers and the requirement for optimization of medical therapy during the run-in period.”
BackgroundNguyen, K. T., & Körner, J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0481-5 · Cited by 51
Esposito, K., Chiodini, P., Capuano, A., Maiorino, M. I., Bellastella, G., & Giugliano, D. (2013) · Endocrine · doi:10.1007/s12020-013-0090-0 · Cited by 54
He, L., Wang, H., Gu, C., He, X., Zhao, L., & Tong, X. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1081657 · Cited by 54
Attal, S., Mahmoud, M. H., Aseel, M. T., Candra, A., Amuna, P., Elnagmi, M., Abdallah, M., Ismail, N., Razek, A. A. K. A., Albaw, D., et al. (2019) · International Journal of Endocrinology · doi:10.1155/2019/3519093 · Cited by 47
Harding, J. L., Li, Y., Burrows, N. R., Bullard, K. M., & Pavkov, M. E. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.09.012 · Cited by 46
Self-citationRibu, L., Holmen, H., Torbjørnsen, A., Wahl, A. K., Grøttland, A., Småstuen, M. C., Elind, E., Bergmo, T. S., Breivik, E., & Årsand, E. (2013) · JMIR Research Protocols · doi:10.2196/resprot.2768 · Cited by 45
“Although medical competence for treating diabetes is improving and knowledge about treatment and lifestyle factors relating to T2D is substantial, most people with this disease do not achieve metabolic control [4,5], and can therefore experience diabetic complications [6].”
BackgroundDavidson, J. A., & Kuritzky, L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2819 · Cited by 48
Diabetes: An Update on the Pandemic and Potential Solutions
Ali, M. K., Siegel, K. R., Chandrasekar, E. K., Tandon, N., Montoya, P. A., Mbanya, J. C., Chan, J. C. N., Zhang, P., & Narayan, K. M. V. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0518-9_ch12 · Cited by 71
Self-citationCosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 44
Differences in U.S. Rural-Urban Trends in Diabetes ABCS, 1999–2018
Mercado, C. I., Bullard, K. M., Gregg, E. W., Ali, M. K., Saydah, S., & Imperatore, G. (2021) · Diabetes Care · doi:10.2337/dc20-0097 · Cited by 52
“Previous analyses have documented substantial improvements in the management of ABCS until 2010 (17,18) with stagnation thereafter (19).”
Self-citationChandran, A., Bonafede, M. K., Nigam, S., Saltiel-Berzin, R., Hirsch, L. J., & Lahue, B. J. (2015) · PubMed Central · Cited by 62
Barriers and enablers of type 2 diabetes self‐management in people with severe mental illness
Mulligan, K., McBain, H. B., Lamontagne-Godwin, F., Chapman, J., Haddad, M., Jones, J., Flood, C., Thomas, D. A., & Simpson, A. (2017) · Health Expectations · doi:10.1111/hex.12543 · Cited by 56
Perilla Oil Supplementation Improves Hypertriglyceridemia and Gut Dysbiosis in Diabetic KKAy Mice
Wang, F., Zhu, H., Hu, M., Wang, J., Xia, H., Yang, X., Yang, L., & Sun, G. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800299 · Cited by 47
Sugiyama, T., Imai, K., Ihana‐Sugiyama, N., Tanaka, H., Yanagisawa‐Sugita, A., Sasako, T., Higashi, T., Okamura, T., Yamauchi, T., Ueki, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.029 · Cited by 46
Chen, Y., Dong-liang, H., Yang, T., Zhou, H., Xiang, S., Shen, L., Wen, J., Chen, S., Peng, S., & Gan, Y. (2020) · BMC Public Health · doi:10.1186/s12889-020-08552-5 · Cited by 49
Development and Regulatory Challenges for Peptide Therapeutics
Zane, D., Feldman, P. L., Sawyer, T. K., Sobol, Z., & Hawes, J. J. (2020) · International Journal of Toxicology · doi:10.1177/1091581820977846 · Cited by 43
“Approximately 50% of treated diabetic patients are not at goal, with low adherence rates across all classes of therapy and poor persistence on treatment, particularly with injectable drugs.(9) Glucagon-like peptide-1 receptor agonists are effective, welltolerated therapeutic options but limited by the need to administ…”
BackgroundRicci‐Cabello, I., Ruíz-Pérez, I., Rojas‐García, A., Pastor‐Moreno, G., & Gonçalves, D. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084464 · Cited by 46
“in the US [3], Europe [4], and Latin America [5] remains suboptimal, highlighting the existence of important disparities in”
BackgroundWinkley, K., Upsher, R., Stahl, D., Pollard, D., Brennan, A., Heller, S. R., & Ismail, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001150 · Cited by 41
Mora, P., Buskirk, A., Lyden, M., Parkin, C. G., Borsa, L., & Petersen, B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0206 · Cited by 41
“0%.(23,24) A major contributor to poor glycemic control is difficulty adhering to prescribed self-management regimens.”
BackgroundCai, X., Hu, D., Pan, C., Li, G., Lu, J., Ji, Q., Su, B., Tian, H., Qu, S., Weng, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44169-4 · Cited by 50
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Di Mauro, A., Tuccinardi, D., Watanabe, M., Del Toro, R., Monte, L., Giorgino, R., Rampa, L., Rossini, G., Kyanvash, S., Soare, A., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3406 · Cited by 39
Boronikolos, G. C., Menge, B. A., Schenker, N., Breuer, T. G. K., Otte, J., Heckermann, S., Schliess, F., & Meier, J. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3538-3 · Cited by 44
Carson, A. P., Tanner, R. M., Yun, H., Glasser, S. P., Woolley, J. M., Thacker, E. L., Levitan, E. B., Farkouh, M. E., Rosenson, R. S., Brown, T. M., et al. (2014) · Annals of Epidemiology · doi:10.1016/j.annepidem.2014.05.007 · Cited by 39
Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia
Bailey, C. J. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12906 · Cited by 40
Computational content analysis of negative tweets for obesity, diet, diabetes, and exercise
Shaw, G. B., & Karami, A. (2017) · Proceedings of the Association for Information Science and Technology · doi:10.1002/pra2.2017.14505401039 · Cited by 44
Pilla, S. J., Segal, J. B., & Maruthur, N. M. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-04843-9 · Cited by 48
Aronson, R., Orzech, N., Ye, C., Goldenberg, R., & Brown, V. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12257 · Cited by 38
Watanabe, Y., Nakayama, K., Taniuchi, N., Horai, Y., Kuriyama, C., Ueta, K., Arakawa, K., Senbonmatsu, T., & Shiotani, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116851 · Cited by 39
“However, almost half of the diabetic adults in the United States still do not meet the targets for glycemic control [9].”
BackgroundBohn, B., Kerner, W., Seufert, J., Kempe, H., Jehle, P. M., Best, F., Füchtenbusch, M., Knauerhase, A., Hofer, M., Rosenbauer, J., et al. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.008 · Cited by 43
“[28] Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW.”
How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?
Deem, J. D., Muta, K., Scarlett, J. M., Morton, G. J., & Schwartz, M. W. (2017) · Diabetes · doi:10.2337/dbi16-0067 · Cited by 49
“Although some individuals can achieve adequate glycemic control with this approach, a large percentage does not (89,90).”
BackgroundNuckols, T. K., Keeler, E. B., Anderson, L., Green, J., Morton, S. C., Doyle, B. J., Shetty, K. D., Arifkhanova, A., Booth, M. S., Shanman, R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1495 · Cited by 46
“72% of patients, particularly younger adults with complications (4).”
BackgroundZohar, Y., Zilberman-Itskovich, S., Koren, S., Zaidenstein, R., Marchaim, D., & Koren, R. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02507-9 · Cited by 43
Wu, H., Lau, E. S. H., Yang, A., Zhang, X., Fan, B., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004173 · Cited by 44
Managing Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 39
Peripheral vascular disease risk in diabetic individuals without coronary heart disease
Wilcox, T., Newman, J. D., Maldonado, T. S., Rockman, C. R., & Berger, J. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.026 · Cited by 42
“Adherence to CHD risk factor modification has also been found to be suboptimal in patients with diabetes [5].”
BackgroundParrinello, C. M., Rastegar, I., Godino, J., Miedema, M. D., Matsushita, K., & Selvin, E. (2015) · Diabetes Care · doi:10.2337/dc15-0016 · Cited by 38
Dungan, K. M., Lyons, S., Manu, K. H., Kulkarni, M., Ebrahim, K., Grantier, C., Harris, C., Black, D., & Schuster, D. (2014) · Endocrine Practice · doi:10.4158/ep14061.or · Cited by 44
A systematic review of studies of web portals for patients with diabetes mellitus
Coughlin, S. S., Williams, L. B., & Hatzigeorgiou, C. (2017) · mHealth · doi:10.21037/mhealth.2017.05.05 · Cited by 40
“Although good glycemic control is associated with improved health outcomes and lower morbidity and premature mortality, almost half of patients with type 2 diabetes do not meet recommended targets for glycemic control, blood pressure control, or low density lipoprotein (LDL) cholesterol control (4).”
Backgroundon behalf of the FinnDiane Study Group, Feodoroff, M., Harjutsalo, V., Forsblom, C. M., & Groop, P. (2018) · Diabetologia · doi:10.1007/s00125-018-4725-9 · Cited by 38
Li, B., Zhou, C., Gu, C., Cheng, X., Wang, Y., Li, C., Ma, M., Fan, Y., Xu, X., Chen, H., et al. (2024) · BMC Public Health · doi:10.1186/s12889-023-17512-8 · Cited by 36
“Cardiovascular diseases (CVD) were defined by self-reported any of the following diseases: self-reported congestive heart failure, coronary heart disease, heart attack, or stroke [21].”
BackgroundNew Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 38
“INTRODUCTION Despite considerable advances in the therapy for type 2 diabetes, blood glucose control remains suboptimal.(1) Physicians and others who are struggling to prevent and minimize diabetes complications among their patients continue to face a number of challenges.”
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers
Kuritzky, L., Reid, T., & Wysham, C. (2019) · Clinical Diabetes · doi:10.2337/cd18-0091 · Cited by 40
“Despite overwhelming evidence supporting intervention, data from the National Health and Nutrition Examination Surveys for the years 1988−2010 indicated that ~33–49% of adults with type 2 diabetes in the United States did not meet the recommended targets for any of these individual parameters (4,5).”
BackgroundPharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 40
“vascular risk factors [4,10,11], including hyperglycemia [6], was”
BackgroundThe rising cost of diabetes care in the USA
Peter, P. R., & Lipska, K. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00519-7 · Cited by 36
Meta-analysis of bariatric surgery versus non-surgical treatment for type 2 diabetes mellitus
Wu, G.-Z., Cai, B., Yu, F., Fang, Z., Fu, X.-L., Zhou, H.-S., Zhang, W., & Tian, Z.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.11961 · Cited by 35
“However, only partially patients achieve adequate glycemic control and a reduction in cardiovascular risk [4-6].”
BackgroundSakak, F. R., Moslehi, N., Niroomand, M., & Mirmiran, P. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02419-6 · Cited by 37
Lee, L., Hou, Y.-C., Hsieh, Y.-Y., Chen, Y., Shen, Y., Lee, I., Shih, M.-C. M., Hou, W., & Liu, H. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104653 · Cited by 35
Tanaka, H., Tomio, J., Sugiyama, T., & Kobayashi, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000291 · Cited by 37
“These studies show that the ‘evidence–practice gap’ among healthcare providers is still a main barrier to the quality of diabetes care, although the gap is gradually decreasing.(17) 21 23 In Japan, patients’ access to the health service is generally high because of universal health insurance coverage and a generous be…”
BackgroundResultInfluentialLa obesidad: la verdadera pandemia del siglo xxi
Villalobos, J. Á. C. (2016) · Cirugía y Cirujanos · doi:10.1016/j.circir.2016.08.001 · Cited by 43
Lim, L., Tan, A. T. B., Moses, K., Rajadhyaksha, V., & Chan, S. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.008 · Cited by 35
“The prevalence of diabetes among adults aged 18–44 years in the United States was 13.0%, based on the National Health and Nutrition Examination Survey (NHANES) data (Ali et al., 2013).”
BackgroundInfluentialInfluence of Diabetes on Trends in Perioperative Cardiovascular Events
Newman, J. D., Wilcox, T., Smilowitz, N. R., & Berger, J. S. (2018) · Diabetes Care · doi:10.2337/dc17-2046 · Cited by 37
“outpatients with DM has also been reported (20).”
BackgroundCardiovascular disease in diabetes type 2: current concepts
Rosengren, A. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12804 · Cited by 40
Yamada, M. H., Fujihara, K., OSAWA, T., Yamamoto, M., Kaneko, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., YAMANAKA, N., Seida, H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00168 · Cited by 36
Illness perceptions among patients with type 2 diabetes mellitus: A cross-sectional study.
Tang, J., & Gao, L.-L. (2019) · International Journal of Nursing Practice · doi:10.1111/ijn.12801 · Cited by 28
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
“Also, the success in targeting concomitantly the glycemic, dyslipidemic and hypertensive diseases of T2D is less than 25% [28, 29].”
BackgroundHeller, S. R., Geybels, M. S., Iqbal, A., Liu, L., Wagner, L., & Chow, E. (2021) · Diabetologia · doi:10.1007/s00125-021-05556-7 · Cited by 37
“There is considerable evidence that individuals with type 1 and type 2 diabetes benefit greatly from maintaining good glycaemic control [1, 2]; however, many do not reach their treatment targets [3].”
BackgroundChen, R., Cheadle, A., Johnson, D., & Duran, B. (2014) · The Diabetes Educator · doi:10.1177/0145721714546721 · Cited by 31
The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts
Myerson, R. M., & Laiteerapong, N. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0712-z · Cited by 39
Clinical features and therapeutic perspectives on hypertension in diabetics
Katayama, S., Hatano, M., & Issiki, M. (2018) · Hypertension Research · doi:10.1038/s41440-017-0001-5 · Cited by 39
“One reason for this may be the progress in the treatment of diabetes and hypertension during this period [5].”
BackgroundPathways between food insecurity and glycaemic control in individuals with type 2 diabetes
Walker, R. J., Williams, J. S., & Egede, L. E. (2018) · Public Health Nutrition · doi:10.1017/s1368980018001908 · Cited by 33
“Despite significant research into lifestyle interventions focused on improving glycaemic control and diabetes outcomes, national estimates suggest nearly half of those diagnosed with diabetes do not meet targets for glycaemic control and only 14% meet combined targets for glycaemic control, blood pressure and lipids((…”
BackgroundEngelman, M., & Ye, L. Z. (2019) · Emerald Group Publishing Limited eBooks · doi:10.1108/s1057-629020190000019008 · Cited by 39
“This research has informed clinical strategies for managing the disease as well as campaigns aiming to educate the public about diabetes prevention and incentivize smoking cessation, increased exercise, and healthier diets (Ali et al., 2013).”
BackgroundMichiels, Y., Bugnon, O., Chicoye, A., Dejager, S., Moisan, C., Allaert, F., Hunault, C., Romengas, L., Méchin, H., & Vergès, B. L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00957-y · Cited by 36
Riordan, F., McHugh, S., O’Donovan, C., Mtshede, M. N., & Kearney, P. M. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05676-7 · Cited by 37
Shin, J., Wang, D., Fernandes, G. F., Daya, N. R., Grams, M. E., Golden, S. H., Rajpathak, S. N., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2541 · Cited by 34
Ando, W., Horii, T., Uematsu, T., Hanaki, H., Atsuda, K., & Otori, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-96720-x · Cited by 38
Cardiovascular drugs that increase the risk of new-onset diabetes
Ong, K. L., Barter, P. J., & Waters, D. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.025 · Cited by 35
Laiteerapong, N., Fairchild, P. C., Chou, C.-H., Chin, M. H., & Huang, E. S. (2014) · Medical Care · doi:10.1097/mlr.0000000000000255 · Cited by 34
Halon, D. A., Azencot, M., Rubinshtein, R., Zafrir, B., Flugelman, M. Y., & Lewis, B. S. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003226 · Cited by 33
Metadata
- Authors
- Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W.
- Affiliations
- Centers for Disease Control and Prevention (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-25
- Volume
- 368
- Issue
- 17
- Pages
- 1613-1624
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124234371
- Cited by
- 979
- References
- 40
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 31 · 2023: 45 · 2022: 57 · 2021: 61 · 2020: 77 · 2019: 106 · 2018: 98 · 2017: 112 · 2016: 106 · 2015: 112 · 2014: 97 · 2013: 33
- FWCI
- 91.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes management, glycemic control, HbA1c, blood pressure control, LDL cholesterol, tobacco use, coronary heart disease risk, preventive medicine, annual eye examination, foot examination, influenza vaccination, pneumococcal vaccination, self-monitoring of blood glucose, health disparities, NHANES, Behavioral Risk Factor Surveillance System
- MeSH terms
- Adolescent, Adult, Aged, Diabetes Mellitus, Female, Health Promotion, Glycated Hemoglobin, Humans, Male, Middle Aged, Nutrition Surveys, Patient Compliance, Risk Factors, Socioeconomic Factors, United States, Body Mass Index, Outcome Assessment, Health Care, Age Distribution, Sex Distribution, Quality Indicators, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.